Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Thurau

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Frontiers in Medicine|November 3, 2022
A new small molecule DHODH-inhibitor [KIO-100 (PP-001)] targeting activated T cells for intraocular treatment of uveitis - A phase I clinical trialStephan Thurau, Christoph M E Deuter, Arnd Heiligenhaus, et al.
Autoimmunity Reviews|February 1, 2017
Inflammatory eye disease: Pre-treatment assessment of patients prior to commencing immunosuppressive and biologic therapy: Recommendations from an expert committeeDenis Wakefield, Peter McCluskey, Gerhild Wildner, et al.
Ocular Immunology and Inflammation|May 13, 2021
Uveitis in Tumor Patients Treated with Immunological Checkpoint- and Signal Transduction Pathway-InhibitorsStephan Thurau, Hendrik Engelke, Peter McCluskey, et al.
Ophthalmology|October 4, 2016
Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA)Quan Dong Nguyen, Pauline T Merrill, W Lloyd Clark, et al.
International Journal of Radiation Biology|January 19, 2021
Posterior subcapsular cataracts are a late effect after acute exposure to 0.5 Gy ionizing radiation in miceSarah Kunze, Alexander Cecil, Cornelia Prehn, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Frontiers in Medicine|November 3, 2022
A new small molecule DHODH-inhibitor [KIO-100 (PP-001)] targeting activated T cells for intraocular treatment of uveitis - A phase I clinical trialStephan Thurau, Christoph M E Deuter, Arnd Heiligenhaus, et al.
Autoimmunity Reviews|February 1, 2017
Inflammatory eye disease: Pre-treatment assessment of patients prior to commencing immunosuppressive and biologic therapy: Recommendations from an expert committeeDenis Wakefield, Peter McCluskey, Gerhild Wildner, et al.
Ocular Immunology and Inflammation|May 13, 2021
Uveitis in Tumor Patients Treated with Immunological Checkpoint- and Signal Transduction Pathway-InhibitorsStephan Thurau, Hendrik Engelke, Peter McCluskey, et al.
Ophthalmology|October 4, 2016
Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA)Quan Dong Nguyen, Pauline T Merrill, W Lloyd Clark, et al.
International Journal of Radiation Biology|January 19, 2021
Posterior subcapsular cataracts are a late effect after acute exposure to 0.5 Gy ionizing radiation in miceSarah Kunze, Alexander Cecil, Cornelia Prehn, et al.
Pageof 4